Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Despite vaccines having some degree of efficacy against SARS-CoV-2, vaccinated patients around the world are still getting infected and capitulating to COVID-19. Antiviral drugs could be the answer.

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.

Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has initiated dosing in the Phase 2/3 trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.  The trial is designed to enroll 248 patients.

Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity. The trial is designed to enroll 248 patients.

Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Jiayin Group Inc - ADR

NanoVibronix

Which penny stocks are on your September watchlist? The post Top Penny Stocks to Watch To Stay Ahead in September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch To Stay Ahead in September 2021

New Oriental Education & Technology Group

Transocean

Reddit penny stocks are in focus following the meme stock rally; here's 3 to watch The post Trending Reddit Penny Stocks You Need to Know About Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Reddit Penny Stocks You Need to Know About Now

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company's Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr. Hopkins is departing to pursue new opportunities after serving the Company for the past 14 years. Management has established a comprehensive transition plan to maintain full continuity across all finance functions as Mr. Hopkins departs.

Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events

Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly.

Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient's Cells

NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19

Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”

Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline

Adamis Announces Agreement to Sell Portion of US Compounding Business

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector of Election's certified results from the Company's 2021 Annual Meeting of Stockholders (the “Annual Meeting”), each of the Company's nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Electi

Adamis Announces Results of 2021 Annual Meeting of Stockholders

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company's Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on July 16, 2021. In addition, the Board issued the following statement: “Ahead of this year's Annual Meeting, the Board prioritized engaging with stockholders and gathering feedback regarding the Comp

Adamis Urges Stockholders to Vote to Reelect the Company's Board of Directors at Upcoming Annual Meeting on Friday, July 16th

Acasti Pharma

Ampio Pharmaceuticals Inc

BIOLASE

Jaguar Health

Northwest Biotherapeutics, Inc.

Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?

Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders. *** July 1, 2021 Dear Stockholders, The Board of Directors (the "Board") appreciates your continued investment in Adamis Pharmaceuticals Corporation ("Adamis" or the "Company" or “we”). The Board also appreciates the feedback that many stockholders have provided in recent weeks. As we work to position Adamis for long-term success, please trust that this input will be care

Adamis Sends Letter to Stockholders to Address Jerald A. Hammann's Costly, Distracting and Misguided Campaign

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today issued the below letter to stockholders. June 28, 2021 Dear Stockholder, The Board of Directors (the "Board") appreciates your continued investment in Adamis Pharmaceuticals Corporation ("Adamis" or the "Company"). Ahead of our Annual Meeting of Stockholders on July 16th (the "Annual Meeting"), we want to once again urge you to vote to re-elect all five members of the Board. We believe maintaining continuity in

Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Adamis Pharmaceuticals (ADMP) Stock?

Predictive Oncology Inc

Electrameccanica

Are these Robinhood penny stocks the best to watch in 2021? The post Best Penny Stocks to Buy on Robinhood?

Best Penny Stocks to Buy on Robinhood? 3 For Your Morning Watchlist

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent the below letter to stockholders. The letter has been signed by all five members of the Company's Board of Directors: Howard C. Birndorf, Roshawn Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams. *** June 14, 2021 Dear Stockholder, The Board of Directors (the "Board") than

Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders

Adamis Pharmaceuticals is preparing to launch a Phase II/III study with TEMPOL in COVID-19 patients. The NIH recently reported that they found TEMPOL inhibits viral replication. I believe TEMPOL could be a leading COVID-19 therapeutic that can be employed at all stages of the infection. I provide some background on TEMPOL.

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 13% this morning. This is why it happened.

ADMP Stock Price: Over 13% Increase Explanation

The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ: ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose. The agency's target action date is November 12.

Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose

FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021

Adamis Provides Update on ZIMHI™

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has highlighted that the National Institutes of Health (NIH) has identified its experimental drug, Tempol, as a potentially potent antiviral for COVID-19. According to a study of cell cultures conducted by NIH researchers, Tempol demonstrated an ability to limit SARS-CoV-2 infection by impairing the activity of a viral enzyme known as RNA replicase.

Adamis Pharma Stock Jumps as NIH Sees Promise in Tempol for COVID-19

The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased by over 10% pre-market. This is why it happened.

News for Adamis Pharmaceuticals Stock (ADMP)